Latest On Oncolytics Biotech Inc (ONCY):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-26 14:43 EST | News | Oncolytics falls 16% after mid-stage data for breast cancer therapy | N/A |  |
| 2023-05-05 17:10 EST | News | Oncolytics Biotech Inc. (ONCY) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-05 17:10 EST | News | Oncolytics Biotech GAAP EPS of -$0.10 in-line | N/A | |
| 2023-05-04 15:09 EST | News | Oncolytics Biotech Q1 2023 Earnings Preview | N/A | |
| 2023-03-04 00:55 EST | News | Oncolytics Biotech Inc. (ONCY) Q4 2022 Earnings Call Transcript | N/A | |
About Oncolytics Biotech Inc (ONCY):
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
General
- Name Oncolytics Biotech Inc
- Symbol ONCY
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 25
- Last Split Factor10:95
- Last Split Date2018-05-25
- Fiscal Year EndDecember
- IPO Date1999-11-08
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.oncolyticsbiotech.com
Valuation
- Price/Book (Most Recent Quarter) 8.32
Financials
- Most Recent Quarter 2020-12-31
- Return on Assets -59%
- Return on Equity -183%
- Earnings Per Share -$0.83
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
Highlights
- Market Capitalization 157.62 million
- Book Value Per Share $0.40
Share Statistics
- Shares Outstanding 43.3 million
- Shares Float 51.19 million
- % Held by Insiders 124%
- % Held by Institutions 1.85%
- Shares Short 891018
- Shares Short Prior Month 828747
- Short Ratio 0.36
- Short % of Float 2%
- Short % of Shares Outstanding 2%
Technicals
- Beta 1.93
- 52 Week High $4.19
- 52 Week Low $1.06
- 50 Day Moving Average 3
- 200 Day Moving Average 2.46
Dividends
- Dividend Date 2018-05-25
- ExDividend Date N/A
- Dividend Yield 0%
Oncolytics Biotech Inc (ONCY) Dividend Calendar:
ONCY's last dividend payment was made to shareholders on May 25, 2018.
Oncolytics Biotech Inc (ONCY) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Oncolytics Biotech Inc (ONCY) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Oncolytics Biotech Inc (ONCY) Chart:
Oncolytics Biotech Inc (ONCY) News:
Below you will find a list of latest news for Oncolytics Biotech Inc (ONCY) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Oncolytics Biotech Inc (ONCY) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest ONCY Trades:
Oncolytics Biotech Inc (ONCY) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-10-27 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-10-19 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-08-26 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-08-04 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-08-04 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-06-25 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-06-25 | SUPPL (Voluntary Supplemental Material by Foreign Issuers [Section 11(a)]) | |
| 2020-06-25 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-06-25 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-06-23 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-06-17 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-06-16 | SUPPL (Voluntary Supplemental Material by Foreign Issuers [Section 11(a)]) | |
| 2020-06-16 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-06-15 | EFFECT (Notice of Effectiveness) | |
| 2020-06-12 | F-10/A (Registration Statement for Securities of certain Canadian Issuers.) | |
| 2020-06-08 | F-10 (Registration Statement for Securities of certain Canadian Issuers.) | |
| 2020-06-08 | F-X (Appointment of Agent for Service of Process and Undertaking) | |
| 2020-06-04 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-05-29 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-05-26 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |